The implants that have been awarded are the following:
-
Quadra-H, which was awarded the 10A* ODEP rating
-
Quadra-C, which was awarded the 5A* ODEP rating
-
X-Acta, which was awarded the 3A* ODEP rating
These excellent ratings (A* is the strongest) witness the effectiveness of the Medacta cementless and cemented Hip Stems and highlight Medacta’s commitment to gathering the highest standard of evidence to support our products. The ODEP (Orthopaedic Data Evaluation Panel) is considered one of the most robust and reliable rating systems by the orthopaedic surgeon community.
According to ODEP rating criteria, Quadra-H, Quadra-C and X-Acta have been evaluated in a minimum cohort of 500, 250, 150 hips respectively, demonstrating an actual revision rate of less than 5% at ten years, less than 3.5% at five years and less than 3% at three years, respectively. Furthermore, the A* rating for Quadra-C and X-Acta demonstrates Kaplan-Meier survivorship data in line with a cumulative percent of revision lower than 5% at ten years. (For more information about ODEP, please visit the website:
www.odep.org.uk.)
The recent ratings exemplify Medacta's continuous commitment to provide innovative and safe solutions with exceptional outcomes for both patients and healthcare systems around the world. A crucial role in this process is played by
Medacta’s M.O.R.E. Institute, which supports professionals in the field of research and education through effective medical education programs, and surgeon-to-surgeon educational opportunities to share best practices and clinical experience.
